SREBP1 INDUCES RESISTANCE TO HIF-2α ANTAGONIST IN CLEAR CELL RENAL CELL CARCINOMA

被引：0
|
作者：
Son, Da Hyeon
Lee, Young Ju
Kim, Hyo Eun
Kim, Eun Song
Park, Sung Yul
Yoon, Young Eun
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD51-08
引用
收藏
页码：E1067 / E1068
页数：2
相关论文
共 50 条
  • [41] TBC1D5 reverses the capability of HIF-2α in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy
    Huang, Yu
    Xiong, Zhiyong
    Wang, Jianjun
    Gao, Yafen
    Cao, Qi
    Wang, Decai
    Shi, Jian
    Chen, Zhixian
    Yang, Xiong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [42] Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients
    Emerling, Brooke M.
    Benes, Cyril H.
    Poulogiannis, George
    Bell, Eric L.
    Courtney, Kevin
    Liu, Hui
    Choo-Wing, Rayman
    Bellinger, Gary
    Tsukazawa, Kazumi S.
    Brown, Victoria
    Signoretti, Sabina
    Soltoff, Stephen P.
    Cantley, Lewis C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (09) : 3483 - 3488
  • [43] Novel HIF-2α targeted RNA. therapeutic for renal cell carcinoma
    Wong, So
    Cheng, Weijun
    Wakefield, Darren
    Almeida, Aaron
    Blokhin, Andrei
    Hamilton, Holly
    Subbotin, Vladimir
    Hegge, Julia
    Neal, Zane
    Zhang, Guofeng
    Rozema, David
    Lewis, David
    Kanner, Steven
    CANCER RESEARCH, 2016, 76
  • [44] The VHL/HIF axis in clear cell renal carcinoma
    Shen, Chuan
    Kaelin, William G., Jr.
    SEMINARS IN CANCER BIOLOGY, 2013, 23 (01) : 18 - 25
  • [45] Targeting hypoxia inducible factor (HIF)-2α with AB521, a novel and potent small molecule HIF-2α inhibitor, for the treatment of clear cell renal cell carcinoma
    Piovesan, Dana
    Cho, Soonweng
    Lawson, Kenneth V.
    Liao, Kai H.
    Foster, Paul G.
    Cheng, Tzuling
    Walters, Matthew J.
    Gauthier, Kelsey E. Sivick
    CANCER RESEARCH, 2023, 83 (16)
  • [46] MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
    Fengqi Yan
    Qinhao Wang
    Mingyuan Xia
    Yi Ru
    Wei Hu
    Guang Yan
    Xin Xiong
    Mei Zhang
    Jiancai Wang
    Qi Li
    Bo Zhang
    He Wang
    Wei Lin
    Guojun Wu
    Xia Li
    Cancer Biology & Medicine, 2022, (06) : 818 - 835
  • [47] Evolution of the HIF targeted therapy in clear cell renal cell carcinoma
    Golijanin, Borivoj
    Malshy, Kamil
    Khaleel, Sari
    Lagos, Galina
    Amin, Ali
    Cheng, Liang
    Golijanin, Dragan
    Mega, Anthony
    CANCER TREATMENT REVIEWS, 2023, 121
  • [48] MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
    Yan, Fengqi
    Wang, Qinhao
    Xia, Mingyuan
    Ru, Yi
    Hu, Wei
    Yan, Guang
    Xiong, Xin
    Zhang, Mei
    Wang, Jiancai
    Li, Qi
    Zhang, Bo
    Wang, He
    Lin, Wei
    Wu, Guojun
    Li, Xia
    CANCER BIOLOGY & MEDICINE, 2022, 19 (06) : 818 - 835
  • [49] E2F3 upregulation promotes tumor malignancy through the transcriptional activation of HIF-2α in clear cell renal cell carcinoma
    Gao, Yu
    Li, Hongzhao
    Ma, Xin
    Fan, Yang
    Ni, Dong
    Zhang, Yu
    Huang, Qingbo
    Liu, Kan
    Li, Xintao
    Wang, Lei
    Yao, Yuanxin
    Ai, Qing
    Zhang, Xu
    ONCOTARGET, 2017, 8 (33) : 54021 - 54036
  • [50] Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation
    Chan, Kok Hoe
    Li, Ningjing
    Lador, Ran
    Amsbaugh, Mark
    Gonzalez, Anneliese
    Cen, Putao
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
12345